1-O-hexyl-2,3,5-trimethylhydroquinone is a synthetic compound with the chemical formula C15H26O2. It belongs to the family of **alkylated hydroquinones**, specifically substituted with a hexyl group at the 1-position and three methyl groups at the 2, 3, and 5 positions.
**Importance in Research:**
This compound, often abbreviated as **THQ-C6**, is gaining significant attention in scientific research due to its potential applications in various fields, including:
* **Antioxidant Properties:** THQ-C6 exhibits strong antioxidant activity, surpassing the commonly known antioxidant, butylated hydroxytoluene (BHT). This property stems from its ability to readily donate electrons to neutralize free radicals, thus protecting cells from oxidative damage.
* **Cancer Research:** Studies are exploring THQ-C6's potential to inhibit cancer cell growth. Its antioxidant activity, along with its ability to modulate signaling pathways involved in cancer development, makes it a promising candidate for cancer therapy.
* **Neuroprotection:** THQ-C6 shows protective effects against neuronal damage caused by oxidative stress. This makes it a potential therapeutic agent for neurodegenerative diseases like Alzheimer's and Parkinson's disease.
* **Cosmetic Applications:** The antioxidant properties of THQ-C6 make it suitable for use in cosmetic products. It can help protect skin from environmental damage caused by UV radiation and pollution.
* **Materials Science:** THQ-C6 is being investigated for its potential to act as a stabilizer in polymer materials, preventing degradation caused by oxidation.
**Key Advantages:**
* **High Antioxidant Activity:** THQ-C6's strong antioxidant activity makes it effective in protecting cells from damage.
* **Biocompatibility:** It exhibits good biocompatibility, making it suitable for applications in biological systems.
* **Synthetic Availability:** THQ-C6 can be synthesized efficiently, making it readily accessible for research and potential commercial use.
**Ongoing Research:**
Researchers are actively exploring the potential of THQ-C6 in various fields. This includes:
* **Developing drug delivery systems:** THQ-C6's antioxidant properties could be utilized to protect therapeutic agents during delivery to target tissues.
* **Optimizing its chemical structure:** Modifications to the molecule's structure could further enhance its potency and effectiveness.
* **Conducting clinical trials:** Clinical trials are necessary to evaluate the safety and efficacy of THQ-C6 for therapeutic applications in humans.
**In summary,** 1-O-hexyl-2,3,5-trimethylhydroquinone (THQ-C6) is a promising compound with significant potential across multiple research fields. Its strong antioxidant properties, biocompatibility, and synthetic accessibility make it a valuable tool for investigating and potentially developing new therapies, materials, and cosmetic products.
ID Source | ID |
---|---|
PubMed CID | 119193 |
CHEMBL ID | 3182532 |
SCHEMBL ID | 688955 |
MeSH ID | M0218400 |
Synonym |
---|
4-(hexyloxy)-2,3,6-trimethylphenol |
1-o-hexyl-2,3,5-trimethylhydroquinone |
148081-72-5 |
phenol, 4-(hexyloxy)-2,3,6-trimethyl- |
ccris 7478 |
hx-1171 |
FT-0669213 |
4-hexoxy-2,3,6-trimethylphenol |
dtxcid50697 |
tox21_301245 |
dtxsid1020697 , |
NCGC00255289-01 |
cas-148081-72-5 |
hx 1171 |
70bk60i8rp , |
unii-70bk60i8rp |
hexyl-2,3,5-trimethylhydroquinone, 1-o- |
hexyloxy trimethylphenol |
hexyloxy trimethylphenol [inci] |
S5314 |
4-hexyloxy-2,3,6-trimethylphenol |
hthq |
H1741 |
SCHEMBL688955 |
CHEMBL3182532 |
HY-100768 |
AKOS030239845 |
AS-63071 |
CS-5979 |
J-008439 |
DB12162 |
BCP19301 |
EX-A2453 |
hthq(1-o-hexyl-2,3,5-trimethylhydroquinone) |
A16335 |
mfcd00927896 |
CCG-266843 |
Q27265853 |
AC-35787 |
Excerpt | Reference | Relevance |
---|---|---|
" Pharmacokinetic parameters were obtained by non-compartmental analysis." | ( Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers. Bae, KS; Choi, HY; Han, KG; Kang, JK; Kim, YH; Lee, SH; Lim, HS; Miki, T, 2015) | 0.42 |
"50 hours and slowly eliminated with a terminal half-life of 21." | ( Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers. Bae, KS; Choi, HY; Han, KG; Kang, JK; Kim, YH; Lee, SH; Lim, HS; Miki, T, 2015) | 0.42 |
" The pharmacokinetic profile of HX-1171 was consistent with once-a-day dosing." | ( Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers. Bae, KS; Choi, HY; Han, KG; Kang, JK; Kim, YH; Lee, SH; Lim, HS; Miki, T, 2015) | 0.42 |
Excerpt | Relevance | Reference |
---|---|---|
"2 after repeated dosing for 14 days." | ( Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers. Bae, KS; Choi, HY; Han, KG; Kang, JK; Kim, YH; Lee, SH; Lim, HS; Miki, T, 2015) | 0.42 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 55.6071 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 44.0965 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 39.3668 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 39.3668 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 58.5128 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 30.4322 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063 |
caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 49.1509 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 69.4275 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 24.4107 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 27.6396 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 56.7054 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692; AID720719 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 67.8162 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 55.6071 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 49.2099 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259401; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 34.7962 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 55.8787 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743091 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 12.4489 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
caspase-3 | Homo sapiens (human) | Potency | 49.1509 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 64.3454 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 43.8058 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 42.3473 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1259385; AID1259395 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 55.6071 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 47.8345 | 19.7391 | 45.9784 | 64.9432 | AID1159509; AID1159518 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 27.8261 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 125.9240 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 47.0951 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 57.8252 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 61.8773 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 69.4275 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 61.8773 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 69.4275 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (50.00) | 18.2507 |
2000's | 3 (16.67) | 29.6817 |
2010's | 3 (16.67) | 24.3611 |
2020's | 3 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.60) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (5.26%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (94.74%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |